(Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 001-39513 Outset Medical, Inc. (Exact name of Registrant as specified in its Charter) Delaware 20-0514392 (State or other jurisdiction of ...

A downtrend has been apparent in Outset Medical, Inc. (OM) lately. While the stock has lost 9.9% over the past week, it could witness a trend reversal as a hammer chart pattern was formed in its last trading session. This could mean that the bulls have been able to counteract the bears to help the stock find support.The formation of a hammer pattern is considered a technical indication of nearing a bottom with likely subsiding of selling pressure. But this is not the only factor that makes a bullish case fo ...

Core Viewpoint - In 2025, Bitcoin has underperformed expectations, struggling to maintain its value above $100,000, with only a 5% increase for the year, prompting investors to seek alternative cryptocurrencies that may outperform Bitcoin [1]. Group 1: Alternative Cryptocurrencies - XRP has increased over 400% since the presidential election and 30% in 2025, benefiting from a pro-crypto regulatory environment under the Trump administration, with potential resolution of regulatory issues from the SEC [3][4]. - XRP is speculated to be a candidate for a new spot ETF approval, with current trading around $2.70 and price predictions reaching as high as $10, depending on investor interest in ETFs [5]. - Bittensor has a market cap of nearly $4 billion and is up 3% for the year, focusing on AI projects and recently listed on Coinbase, which boosted its price by 20% [6][8]. - Bittensor has a limited supply of 21 million coins, similar to Bitcoin, contributing to its high price of $450 due to scarcity [9]. - Mantra has seen a 99% increase year-to-date and an astonishing 43,927% since October 2023, focusing on real-world asset tokenization for financial institutions [10][11]. - The asset tokenization market is projected to be a multitrillion-dollar opportunity by 2030, with significant potential for growth in various asset classes [13][14]. Group 2: Market Context - Despite Bitcoin's strong historical performance, XRP, Bittensor, and Mantra are positioned to potentially deliver substantial gains over the next five years, although they carry higher risks [15].

SAN JOSE, Calif., Feb. 24, 2025 (GLOBE NEWSWIRE) -- Outset Medical, Inc. (Nasdaq: OM) (“Outset”), a medical technology company pioneering a first-of-its-kind technology to reduce the cost and complexity of dialysis, today announced that members of management will present at the 45th annual TD Cowen Health Care conference on Tuesday, March 4, 2025, at 2:30 p.m. Eastern time. A live and archived webcast of the presentation will be available on the “Investors” section of the Outset website at https://investors ...

Outset Medical, Inc. (NASDAQ:OM) Q4 2024 Earnings Conference Call February 19, 2025 5:00 PM ET Company Participants Jim Mazzola - Head of Investor Relations Leslie Trigg - Chair and CEO Nabeel Ahmed - Chief Financial Officer Conference Call Participants Marie Thibault - BTIG Shagun Singh - RBC Capital Markets Suraj Kalia - Oppenheimer Operator Good day, and thank you for standing by. Welcome to the Outset Medical Fourth Quarter 2024 Earnings Conference Call. At this time, all participants are in a listen-on ...

Core Insights - Outset Medical reported fourth-quarter earnings that exceeded analysts' expectations, with revenue of $29.5 million surpassing the forecast of $28 million, indicating resilience in revenue growth despite market challenges [2][3] - The company achieved significant improvements in operational efficiency and gross margins, with adjusted gross margin reaching 37.7%, up from 27.1% year-over-year [4][7] Financial Performance - Adjusted EPS loss was $0.37, better than the projected loss of $0.44, and a significant improvement from the loss of $0.54 in Q4 2023 [4] - Net revenue decreased by 3.3% year-over-year from $30.5 million in Q4 2023 to $29.5 million in Q4 2024 [4] - Adjusted net loss was $19.3 million, an improvement from the $27 million loss in the previous year [4] Business Model and Strategy - Outset Medical is known for its Tablo Hemodialysis System, which simplifies dialysis treatment and reduces costs, with a focus on increasing market penetration in acute and home settings [5][6] - The company is enhancing its sales strategies and customer support to broaden the adoption of the Tablo system [6] Operational Highlights - Gross margin improved significantly due to higher average selling prices for consoles and reduced operational costs [7] - Recurring revenue from consumables and services grew by 17% year-over-year, indicating a shift towards sustainable revenue generation [8] - Operating expenses were reduced by 28% year-over-year, contributing to the pathway to profitability [8] Future Outlook - Management anticipates continued improvements in gross margins, aiming for non-GAAP gross margins in the high-30% range [9] - Revenue projections for 2025 estimate growth between $115 million and $125 million, reflecting confidence in market expansion [9] - The company plans to reduce cash usage to under $50 million, enhancing its financial position for future initiatives [10]

Outset Medical, Inc. (OM) came out with a quarterly loss of $0.37 per share versus the Zacks Consensus Estimate of a loss of $0.43. This compares to loss of $0.59 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 13.95%. A quarter ago, it was expected that this company would post a loss of $0.42 per share when it actually produced a loss of $0.39, delivering a surprise of 7.14%.Over the last four quarters, the company has surpas ...

SAN JOSE, Calif., Feb. 19, 2025 (GLOBE NEWSWIRE) -- Outset Medical, Inc. (NASDAQ:OM), a medical technology company pioneering a first-of-its-kind technology to reduce the cost and complexity of dialysis, today reported financial results for the fourth quarter and full year ended December 31, 2024. Fourth Quarter, Year-End Highlights Net revenue of $29.5 million in the fourth quarter and $113.7 million in 2024 were both ahead of the company's prior guidance and preannouncement in January.Gross margin of 36.5 ...

SAN JOSE, Calif., Feb. 13, 2025 (GLOBE NEWSWIRE) -- Outset Medical, Inc. (Nasdaq: OM) (“Outset”), a medical technology company pioneering a first-of-its-kind technology to reduce the cost and complexity of dialysis, today announced it has been notified by the Food and Drug Administration that all issues cited in a Warning Letter the company received in July of 2023 have been addressed. “A commitment to innovation and the advancement of better outcomes in dialysis remains at the core of Outset, which makes t ...

Outset Medical, Inc. (OM) is expected to deliver a year-over-year increase in earnings on lower revenues when it reports results for the quarter ended December 2024. This widely-known consensus outlook gives a good sense of the company's earnings picture, but how the actual results compare to these estimates is a powerful factor that could impact its near-term stock price.The stock might move higher if these key numbers top expectations in the upcoming earnings report, which is expected to be released on Fe ...